2003
DOI: 10.1016/s0001-706x(03)00031-7
|View full text |Cite
|
Sign up to set email alerts
|

Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

7
253
1
17

Year Published

2006
2006
2018
2018

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 316 publications
(291 citation statements)
references
References 29 publications
7
253
1
17
Order By: Relevance
“…This increase may result from the mode of action of PZQ that causes tegumentary damage among other effects, perhaps resulting in greater antigen exposition than that caused by benzimidazoles, which have a less aggressive mode of action (selective degeneration of parasite cytoplasmic microtubules, leading to decreased adenosine triphosphate formation and energy depletion). 36,37 However, this early increment in antigen OD levels was not predictive of antiparasitic efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…This increase may result from the mode of action of PZQ that causes tegumentary damage among other effects, perhaps resulting in greater antigen exposition than that caused by benzimidazoles, which have a less aggressive mode of action (selective degeneration of parasite cytoplasmic microtubules, leading to decreased adenosine triphosphate formation and energy depletion). 36,37 However, this early increment in antigen OD levels was not predictive of antiparasitic efficacy.…”
Section: Discussionmentioning
confidence: 99%
“…Some of them act through the generation of ROS and RNS in parasites (Docampo 1990, Dayan 2003. Studies carried out in recent years have indicated that these compounds may also cause oxidative stress in a host (Pinlaor et al 2008, Dewa et al 2009).…”
Section: Discussionmentioning
confidence: 99%
“…Among the benzimidazole carbamates, albendazole is considered as the most effective, although various undesirable side effects were reported (Reuter et al, 2000), what happened in our case 2. Mebendazole has a lower oral bioavailability and consequently lower plasma levels of the active metabolite than ABZ (Dayan, 2003), but the peak plasma levels of benzimidazoles in individual patients depend also on the metabolic capacity of liver parenchymal cells on cytochrome P450 (Rawden et al, 2000). This could markedly influence the drug´s final the-rapeutical effect.…”
Section: Discussionmentioning
confidence: 99%